Conditions: Neoplasms Carcinoma, Non Small Cell Lung Breast Neoplasms Ovarian Neoplasms
Keywords: ADC 5T4 PF-06263507 solid tumors lung cancer breast cancer ovarian cancer cancer tumors neoplasm metastasis
Enrollment: 26
Healthy volunteers: no

Brief summary:
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: PF-06263507 intervention 2: PF-06263507
Intervention descriptions: intervention 1: Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined. intervention 2: Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.

Protocol document: